The turnover of apolipoprotein B (apo B) (0.192/d). Most subjects exhibited precursor-product relationships between VLDL and IDL, and all did between IDL and light LDL; an analogous relationship between light and heavy LDL was evident in most hyperapo B patients and controls but not in FH patients. Simultaneous injection of differentially labeled LDL fractions and deconvolution analysis showed increased light LDL synthesis with normal conversion into heavy LDL in hyperapo B. whereas in FH conversion of light LDL was reduced and there was independent synthesis of heavy LDL. These data show that the increased concentration of LDL-apo B in hyperapo B is solely due to increased LDL synthesis, which is secondary to increased VLDL synthesis; in contrast, in FH there is both an increase in synthesis of LDL (which is partly VLDL-independent) and reduced catabolism.
Introduction
Evidence that low density lipoprotein (LDL) is heterogenous in terms of particle size and composition has been published by several groups of workers, using a variety of methods of separation (1) (2) (3) (4) (5) (6) . These studies have shown that LDL can be separated into 3-5 subfractions in normal subjects (1, (3) (4) (5) and pa-tients with type IV hyperlipoproteinemia (2) in whom, as pointed out by Fisher (7), heterogeneity seems especially marked. Incubation of LDL with postheparin plasma results in a shift in the distribution of LDL from lighter into heavier subfractions (1) , which suggests the conversion oflarger into smaller particles consequent on lipolysis (3, 5) . Kinetic studies by Phair et al. (8) provide additional support for the existence of precursor-product relationships within the spectrum of LDL particles.
Recently we described a simple means of separating LDL into two major subfractions, fraction 1 or light LDL, and fraction 2 or heavy LDL, using discontinuous density gradient ultracentrifugation, and we documented differences in the densities and composition ofthese fractions between normal subjects and patients with increased plasma levels of LDL-apolipoprotein B (apo B) (6) . The latter fell into two categories: patients with familial hypercholesterolemia (FH), in whom fraction 1 was cholesterol ester-enriched and less dense than normal, and patients with hyperapobetalipoproteinemia (hyperapo B), in whom fraction 2 was cholesterol ester-depleted and denser than normal. As defined previously (9, 10) , the term hyperapo B denotes an increased concentration of LDL-apo B in plasma in the face of a normal concentration of LDL cholesterol, often accompanied by hypertriglyceridemia and associated with coronary heart disease (CHD). An increase in LDL-apo B, hypertriglyceridemia, and a predisposition to CHD are also features of familial combined hyperlipidemia (1 1) , with which hyperapo B undoubtedly overlaps in some instances. The relationship between these two entities and the possibility that an abnormality of apo B metabolism is common to both has recently been discussed in detail elsewhere (12) .
In the present study the turnover of apo B within the main subfractions of LDL and in its precursors, very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL), has been investigated in normal subjects, patients with hyperapo B, and patients with heterozygous FH; a major objective was to determine the mechanisms responsible for the increased levels of LDL-apo B and contrasting changes in LDL composition, which distinguish these two disorders.
Methods
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Blood samples were taken into EDTA at 2-4 hourly intervals during the first 24 h after the injection of labeled lipoproteins and at 12-24 hourly intervals for the next 9 d. Plasma was separated, stored at 4°C for 5-10 d, and then successively ultracentrifuged at d 1.006 and d 1.019 in a 50 Ti rotor (Beckman Instruments, Inc., Fullerton, CA; 40,000 rpm for 16 h at 40C). The VLDL and IDL were recovered after tube slicing for analysis of apo B specific activities. This involved delipidation of samples with ether/ethanol, followed by column chromatography on Sephadex G-1 50 and assay of the leading edge of the apo B peak, which elutes with the void volume, for radioactivity and protein content, as originally described by Sigurdsson et al. (20) . Sample count rates ranged from 100 to 550,000 cpm above background. The absolute catabolic rate (ACR) of apo B in VLDL was calculated as dose injected divided by area under the VLDL specific activity time curve, computed graphically, and the fractional catabolic rate (FCR) was calculated as ACR X body weight divided by pool size (21) . Wherever possible the proportion of VLDL converted to LDL was determined by deconvolution analysis (20) . The turnover of apo B in IDL derived from VLDL was calculated by the method of Zilversmit (22) where the FCR of a product is the increase in its specific activity over any given period of time, divided by the corresponding area between the precursor and product specific activity/time curves. This method can be used only where a precursor/ product relationship exists and was applied only in those instances where the IDL specific activity curve intersected the VLDL specific activity curve at or not more than 2 h before the peak of IDL specific activity was reached. (24) . Plasma volume was estimated as 4.5% of body weight rather than using the values obtained from the 10-min blood sample (20) . In two FH patients 'broad spectrum' IDL (Sf 12-60) was isolated, labeled, and then injected, and its FCR was measured directly by monocompartmental analysis (25) .
Turnover ofapo B in LDL and its subfractions. The FCR of LDL was calculated by multicompartmental analysis of the plasma radioactivity/time curve, as described by Matthews (26) 40 ,000 rpm for 40 h at 10'C (the temperature is critical since this influences the time taken for the gradient to reach equilibrium), as described in detail previously (6) . At the conclusion the gradient was fractionated, using a tube piercer, into three 1-ml fractions (fractions 3-5) followed by visual separation of heavy LDL (fraction 2) usually recovered in -1.25 ml (mean density, 1 
Results
The clinical and biochemical characteristics of the three groups of subjects are detailed in Table I . The hyperapo B patients did not differ greatly from the normal controls with respect to age and relative body weight but all had CHD, documented angiographically. They had significantly higher plasma levels of total cholesterol, triglyceride (five having a type IV phenotype), and VLDL cholesterol than the controls but there was no significant difference between the two groups with respect to LDL cholesterol and HDL cholesterol. However, the hyperapo B patients had significantly higher LDL-apo B levels than normal controls. All Precursor-product relationships between VLDL, IDL, and LDL subfractions. Fig. 1 shows the changes in specific activity of apo B in the plasma of a control subject after injection of l25I-VLDL. The classical precursor-product relationship between specific activity/time curves, where the precursor (VLDL) should intersect the product (IDL) at or just before the latter reaches its maximum, was not observed in this subject nor in another control and two hyperapo B patients, in all of whom the crossover occurred 3 h or more before IDL specific activity had reached its peak. However, in the remainder (see Fig. 2, left) , where the delay was less than 2 h, an attempt was made to calculate the synthesis of IDL from VLDL, using the method of Zilversmit (22) but accepting that the values obtained (Table  III) are only approximate estimates.
The proportion of VLDL-apo B converted into LDL-apo B, calculated by deconvolution analysis, averaged 58% (22-80%) in three control subjects compared with 49% (35-69%) in four hyperapo B patients. In one of the control subjects and two of the hyperapo B patients only 40-60% of the LDL synthesized could be accounted for on the basis of conversion of VLDL, but in the remainder all LDL was derived from VLDL.
Relationships between the specific activity/time curves of IDL and light LDL are shown in Figs. 1 and 2 (left) and between light and heavy LDL in Fig. 1 (right) . All subjects studied exhibited precursor-product relationships between IDL and light LDL including the FH patients given 125I-VLDL (Fig. 3 ) and 1251I-IDL (Fig. 4) . However, in one control subject (No. 10) and one apo B patient (No. 4) there was no precursor-product relationship between light and heavy LDL, as exemplified in Fig.  2 (right); in both these individuals LDL synthesis was only partially accounted for by conversion of VLDL, as noted above. The lack of any such relationship between light and heavy LDL was even more evident in the three FH patients in whom this was studied, irrespective ofwhether the light LDL was originally derived from injected VLDL (Fig. 3) or from injected IDL of Sf (Fig. 4) .
Turnover ofLDL subfractions. The turnover of apo B in the light and heavy fractions of LDL was qualitatively assessed in nine subjects after an injection of unfractionated, singly labeled LDL, which was given primarily to measure total LDL turnover (see Table III ). As illustrated in Fig. 5 , the early part of the specific activity/time curve for light LDL decays faster and is more curvilinear than that of heavy LDL in a control subject. These (Fig. 7, left) , presumably reflecting conversion of unlabeled IDL into light LDL, without affecting heavy LDL turnover (Fig. 7, right) . In FH, no precursor-product relationship was evident between light and heavy LDL, confirming earlier studies in which VLDL or IDL had been injected (Fig. 8, left) . Indeed, the cross-over of specific activities 4 d after injection of heavy LDL (Fig. 8, right) suggests that some of the latter may be converted back to light LDL in this disorder, albeit at a slow rate. Alternatively, it may have been due to an influx ofunlabeled heavy LDL. Turnover rates of light and heavy LDL in the six subjects were determined by analysis ofthe respective radioactivity/time curves and the proportion oflight LDL converted to heavy LDL was calculated by deconvolution analysis of the injected heavy LDL and the heavy LDL derived from injected light LDL. Total The hyperapo B subjects in this study were characterized by plasma levels of LDL-apo B in excess of 120 mg/dl in the face ofLDL cholesterol levels of200 mg/dl or less. This combination was due to an increased concentration of heavy LDL particles, denser than normal and with a reduced content of cholesterol ester (6) . These features and a decrease in particle size tend to be especially marked in hypertriglyceridemic hyperapo B patients; five of our seven hyperapo B patients, all of whom had CHD, fell into that category. It was recently suggested that the RID assay we used over-estimates the concentration of LDLapo B in hypertriglyceridemic plasma because of the penetration into the gel of small VLDL and IDL particles containing apo B (17) . However, we could find no evidence of this since 94% of the apo B in 50 sera that we tested was attributable to LDL, both in normolipidemic and hypertriglyceridemic samples (see Methods). Another potential drawback to this method is the possibility that small LDL particles might diffuse faster into the gel than larger LDL particles, thus giving a spuriously high value in hypertriglyceridemic samples. However, comparison of the Lowry and RID methods of quantitating protein in light and heavy LDL, which differ markedly in size, failed to demonstrate any bias of the RID assay toward heavy LDL (6) . Thus, overestimation of LDL-apo B by RID of plasma, at least in our hands, is relatively slight. Nevertheless, all the hyperapo B patients in this study had an LDL apo B of> 120 mg/dl as measured both in plasma and in its d > 1.019 fraction. Although each of the three hyperapo B families we studied contained first degree relatives with raised LDL-apo B levels, only one family exhibited the pattern of multiple lipoprotein phenotypes, which is characteristic of familial combined hyperlipidemia (11) . The latter disorder includes patients with increased levels of LDL cholesterol and type Ila and Ilb phenotypes, whereas such individuals were, by definition, excluded from the present study. Furthermore, LDL-apo B levels are often but not invariably raised (>120 mg/dl) in familial combined hyperlipidemia (1 1). VLDL-apo B synthesis is known to be increased in patients with the latter disorder (28) (29) (30) , and a similar increase was evident in most of our hyperapo B patients, especially if they were hypertriglyceridemic. The area under the curve method of calculating VLDL-apo B turnover, which we used, gives a lower but more accurate estimate of synthesis than monocompartmental analysis (19) , which fails to take into account the slowly turning-over tail of the specific activity/time curve (30 (31) , who found a strong correlation between LDL synthesis and the concentration of LDL-apo B in plasma. In both studies the FCR of LDL was normal in hyperapo B subjects. The same authors recently described another group of patients with CHD and overproduction of LDL, whose LDL-apo B levels remained normal because ofan increase in FCR; these, they suggest, might represent normolipidemic variants of familial combined hyperlipidemia (32) . Thus, it would seem that oversynthesis ofapo B with normal or even increased LDL catabolism is common to both familial combined hyperlipidemia and hyperapo B. This contrasts with FH where increased synthesis of LDL is accompanied by a decrease in FCR, as observed in this and previous studies (33, 18) .
Since hyperapo B exhibits similar phenotypic features to familial combined hyperlipidemia and both disorders seem to have the same metabolic defect, namely overproduction of apo B, this suggests that they may be identical. However, familial combined hyperlipidemia is considered to be a dominantly inherited disorder (34) , whereas the pattern of distribution of hyperapo B within families is compatible with polygenic inheritance (35) . Until such time as the genetic defect or defects responsible have been identified it seems reasonable to keep an open mind as to whether hyperapo B represents a subgroup of familial combined hyperlipidemia or whether it represents a phenotypically similar but genetically distinct disorder.
The increase in LDL synthesis in hyperapo B is accompanied in most instances by an increase in VLDL-apo B synthesis, as discussed above. Based on the estimate that almost 50% ofVLDL was converted into LDL, this increase in VLDL synthesis accounted for most of the increase in LDL synthesis in hyperapo B. The absence of any increase in IDL synthesis in those hyperapo B patients in whom this could be calculated suggests that increased synthesis of LDL in this disorder seemingly involves direct conversion of VLDL to LDL, as has been postulated in hypertriglyceridemic subjects (36) . In the latter study -20-30% of labeled VLDL was converted directly to LDL without appearing in IDL, while a similar proportion was converted to LDL via IDL, the remainder being completely catabolized. These several fates of VLDL presumably reflect its heterogeneity in hypertriglyceridemic subjects (37) . The possibility of a significant contribution to LDL-apo B levels being derived from a VLDLindependent synthetic pathway in hyperapo B cannot be excluded, however, especially in those subjects in whom a precursor-product relationship between light and heavy LDL was not demonstrable and in whom total LDL synthesis exceeded that derived from VLDL.
The specific activity/time curves ofIDL provide useful qualitative information, but accurate quantitation of IDL turnover is dependent upon a valid estimate of pool size, which may be underestimated if concentrations of apo B are low or losses are high. This may be one explanation of why IDL synthesis rates were often lower than those of LDL. The discrepancy between IDL and LDL synthesis persisted even when 'broad spectrum' IDL (Sf 12-60) was directly injected into two FH patients. This observation, together with the lack of any precursorproduct relationship between light and heavy LDL in all five Turnover ofApolipoprotein B in Hyperapobetalipoproteinemia (40) . Our studies not only explain the increase in LDL-apo B levels in hyperapo B but also have some bearing on the mechanism whereby light LDL is converted to heavy LDL. This process is accentuated in hyperapo B, especially in hypertriglyceridemic subjects in whom heavy LDL is denser, smaller, and more depleted of cholesterol ester than in control subjects (41) or normotriglyceridemic hyperapo B patients (6) . Movement (44) . Reanalysis of those data, after excluding the contribution made by HDL cholesterol, gave almost as good a correlation between the decrease in LDL cholesterol and increase in VLDL cholesterol (r = 0.57, P < 0.005), the differences being confined to cholesterol ester.
Recently, Barter et al. (45) proposed that exchange of cholesterol ester between lipoproteins is a function of the pool size of the individual lipoprotein classes. This being so, an increase in the size of the VLDL pool relative to LDL, as occurs in hyperapo B, would accentuate movement ofcholesterol ester from LDL to VLDL, whereas the reverse would occur in FH. The finding that light LDL is enriched in cholesterol ester and accumulates in the plasma of FH patients, who are deficient in LDL receptors, implies that the conversion of light to heavy LDL is normally dependent on efficient functioning of the receptor-mediated pathway. It is also possible that light LDL has a higher affinity for the LDL receptor than does heavy LDL, as suggested recently (46) . The decrease in the cholesterol/apo B ratio of LDL and increase in FCR, especially of light LDL, induced by measures known to stimulate receptor-mediated LDL catabolism support these conclusions (47) .
Lastly, the question arises as to which is the best method of analyzing LDL turnover. Berman (48) Fisher (50) and, more recently, by Belz et al. (40) .
